Childhood cancers trials in China

In China 609 Also abroad 2483

609 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 2Not yet taking people in China
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
Where
Chengdu
Age
14 years and over
People
66
Run by
West China Hospital
See details and how to joinNCT07715565
Phase 2/3Taking people
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Where
Shanghai
Age
12 years and over
People
85
Run by
Sinotau Pharmaceutical Group
See details and how to joinNCT06398444
No phaseTaking people
Humanistic Continuing Care Via WeChat for Patients Undergoing Thermal Ablation of Papillary Thyroid Carcinoma
Where
Beijing
Age
16 years to 60 years
People
108
Run by
Ming-an Yu
See details and how to joinNCT07302672
Phase 2Not yet taking people in China
Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma
Where
Hangzhou
Age
5 years and over
People
3,300
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07575724
No phaseNot yet taking people in China
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
Where
Tianjin
Age
16 years and over
People
60
Run by
Sizhou Feng
See details and how to joinNCT07703644
No phaseNot yet taking people in China
Full-wrap Versus Conventional Suspension for Reducing Soft Palate Injury Rate in Transoral Surgery
Where
Zhuhai
Age
2 years to 70 years
People
138
Run by
Sun Yat-sen University
See details and how to joinNCT07552545
Early phase 1Not yet taking people in China
Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
Where
Guangzhou
Age
3 years to 75 years
People
18
Run by
Zhujiang Hospital
See details and how to joinNCT07696481
Phase 2Not yet taking people in China
Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)
Where
Changchun, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Hangzhou, Nanjing, Nanning, Shenyang, Shenzhen, Taiyuan, Xiamen, Zhengzhou, Zhongshan
Age
18 days and over
People
230
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07669363
No phaseNot yet taking people in China
Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy
Where
Hangzhou
People
900
Run by
Zhejiang Cancer Hospital
See details and how to joinNCT07689929
Phase 2Not yet taking people in China
PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer
Where
Nanjing
People
35
Run by
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT07690878
No phaseTaking people
Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer
Where
Changsha
People
200
Run by
Central South University
See details and how to joinNCT07063901
No phaseTaking people
CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors
Where
Tianjin
Age
1 year to 70 years
People
18
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07234110
No phaseNot yet taking people in China
Bone Cancer Surgery Prospective Database
Where
Hangzhou
People
400
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07669103
Phase 1Not yet taking people in China
CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation
Where
Shanghai
Age
14 years to 50 years
People
30
Run by
Ruijin Hospital
See details and how to joinNCT07672964
Phase 2Not yet taking people in China
A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy
Where
Nanjing
Age
15 years to 75 years
People
30
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07669740
Phase 1/2Taking people
CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation
Where
Shanghai
People
30
Run by
Ruijin Hospital
See details and how to joinNCT07662369
No phaseNot yet taking people in China
Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers
Where
Beijing
People
50
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT07656740
No phaseTaking people
CONNEctome-guided Navigation for Eloquent-area Tumor Surgery Trial
Where
Beijing
People
200
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07657403
Phase 4Taking people
SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak
Where
Beijing
Age
Up to 85 years
People
966
Run by
Beijing Chao Yang Hospital
See details and how to joinNCT07209787
Phase 2/3Enrolling by invitation
Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
Where
Hangzhou
Age
15 years to 65 years
People
450
Run by
First Affiliated Hospital of Zhejiang University
See details and how to joinNCT07651163
No phaseTaking people
Two-component Radiology-guided Autonomous Cascade Engine (TRACE)
Where
Shenyang
People
54
Run by
Liaoning Cancer Hospital & Institute
See details and how to joinNCT07651644
Phase 2Taking people
Toripalimab Combined With CAV/IE Regimen
Where
Guangzhou
Age
14 years to 70 years
People
134
Run by
Sun Yat-sen University
See details and how to joinNCT04589741
Phase 1/2Not yet taking people in China
PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma
Where
Xuzhou
Age
6 years to 18 years
People
112
Run by
Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07641010
No phaseTaking people
Haplo-Cord HSCT for AML/MDS
Where
Beijing, Chengdu, Fuzhou, Guangzhou
Age
14 years to 60 years
People
82
Run by
Fujian Medical University Union Hospital
See details and how to joinNCT07588360
No phaseTaking people
Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors
Where
Hangzhou
Age
8 years to 18 years
People
600
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07450872